IGEA Pharma NV
SIX:IGPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fino Payments Bank Ltd
NSE:FINOPB
|
IN |
|
Medion AG
XETRA:MDN
|
DE |
|
R
|
Rush Factory Oyj
OMXH:RUSH
|
FI |
|
B
|
BitNine Co Ltd
KOSDAQ:357880
|
KR |
|
CMOC Group Ltd
SSE:603993
|
CN |
|
G
|
Geo Energy Resources Ltd
OTC:GRYRF
|
SG |
|
Bank of Nova Scotia
TSX:BNS
|
CA |
IGEA Pharma NV
Research & Development
IGEA Pharma NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IGEA Pharma NV
SIX:IGPH
|
Research & Development
-€13.4k
|
CAGR 3-Years
52%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
ONWARD Medical NV
XBRU:ONWD
|
Research & Development
-€18m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
IGEA Pharma NV
Glance View
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
See Also
What is IGEA Pharma NV's Research & Development?
Research & Development
-13.4k
EUR
Based on the financial report for Dec 31, 2022, IGEA Pharma NV's Research & Development amounts to -13.4k EUR.
What is IGEA Pharma NV's Research & Development growth rate?
Research & Development CAGR 3Y
52%
Over the last year, the Research & Development growth was 91%. The average annual Research & Development growth rates for IGEA Pharma NV have been 52% over the past three years .
